Natalie Furlong, DO
Family Medicine · Bethel Park, PANPI 1104876473
Payments from drug & device makers
Across 410 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$723
- GSK$642
- Amgen$439
- Bayer$303
- Lilly USA, LLC$261
- plus $2K from 34 others
What the payments were for
- Food & beverage$6,350100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 124 | $2,024 |
| Novo Nordisk | 57 | $723 |
| GSK | 44 | $642 |
| Amgen(2 entities) | 29 | $439 |
| Bayer | 18 | $303 |
| Lilly USA, LLC | 16 | $261 |
| Pfizer | 12 | $195 |
| Abbott | 10 | $190 |
| Esperion Therapeutics, Inc. | 19 | $170 |
| Medtronic(2 entities) | 9 | $156 |
| Amarin Pharma, Inc. | 9 | $153 |
| E.r. Squibb & Sons, L.L.C. | 6 | $109 |
| Abiomed | 3 | $81 |
| Merck | 5 | $74 |
| Teva Pharmaceuticals USA, Inc. | 4 | $59 |
| Ironwood Pharmaceuticals, Inc | 3 | $56 |
| Biohaven Pharmaceuticals, Inc. | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Astellas Pharma US Inc | 3 | $52 |
| Eisai Inc. | 3 | $49 |
| Novartis | 3 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $47 |
| Phathom Pharmaceuticals, Inc. | 2 | $37 |
| Upsher-smith Laboratories LLC | 2 | $36 |
| Antares Pharma, Inc. | 1 | $32 |
| Dexcom, Inc. | 2 | $32 |
| Bioventus LLC | 1 | $28 |
| AstraZeneca | 2 | $26 |
| Inari Medical, Inc. | 1 | $26 |
| Exact Sciences | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Nestle Healthcare Nutrition Inc. | 1 | $24 |
| Si-bone, Inc. | 1 | $20 |
| Heartflow, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $20 |
| Phadia US Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Kvk-tech, Inc. | 3 | $12 |
How this compares
$6,362 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 345 | $328,682 |
| JardianceEmpagliflozin | 178 | $207,272 |
| MounjaroTirzepatide | 174 | $189,876 |
| TradjentaLinagliptin | 226 | $186,800 |
| ProliaDenosumab | 55 | $95,752 |
| OzempicSemaglutide | 69 | $71,172 |
| XareltoRivaroxaban | 69 | $70,345 |
| TrulicityDulaglutide | 52 | $66,670 |
| MyrbetriqMirabegron | 48 | $37,250 |
| Teriparatide | 14 | $32,896 |
| RybelsusSemaglutide | 23 | $29,078 |
| JanuviaSitagliptin Phosphate | 19 | $28,578 |
| Repatha SureclickEvolocumab | 38 | $24,279 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $22,915 |
| LinzessLinaclotide | 34 | $21,734 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $20 | $400,830416 claims |
| PfizerEliquis, Premarin | $195 | $333,405356 claims |
| Lilly USA, LLCMounjaro, Trulicity | $261 | $256,546226 claims |
| Novo NordiskOzempic, Rybelsus, Wegovy | $723 | $116,096104 claims |
| AmgenProlia | $439 | $95,75255 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $642 | $41,38268 claims |
| Astellas Pharma US IncMyrbetriq | $52 | $37,25048 claims |
| MerckJanuvia | $74 | $28,57819 claims |
| AbbVieLinzess, Synthroid | $2,024 | $27,789183 claims |
| NovartisEntresto | $47 | $14,25816 claims |
| AstraZenecaFarxiga | $26 | $13,89814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Bethel Park
- Brian DeyarminBethel Park$491K
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.